Micro- and nanoparticles as platforms for the treatment of fungal infections: present and future perspectives

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Kischkel B, Rossi SA, Santos SR, Nosanchuk JD, Travassos LR, Taborda CP. Therapies and vaccines based on nanoparticles for the treatment of systemic fungal infections. Front. Cell. Infect. Microbiol. 10, 463 (2020). • In this review paper, Kischkel et al. discussed several studies of micro- and nanodrug delivery systems as therapeutic options for the treatment of and vaccination against several fungal infections. The authors had the opportunity to discuss a broader variety of formulations and their applicability focused on major fungal pathogens, making this review paper a must read for any investigator interested in the potential of nanotechnology for treatment and prevention of fungal infections.
  Medline CASGoogle Scholar
• 2. Nett JE, Andes DR. Antifungal agents: spectrum of activity, pharmacology, and clinical indications. Infect. Dis. Clin. North Am. 30(1), 51–83 (2016).
  MedlineGoogle Scholar
• 3. Voltan AR, Quindós G, Alarcón KPM, Fusco-Almeida AM, Mendes-Giannini MJS, Chorilli M. Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy? Int. J. Nanomed. 11, 3715–3730 (2016).
  Medline CASGoogle Scholar
• 4. Han G, Friedman AJ, Friedman JM. Nitric oxide releasing nanoparticle synthesis and characterization. Methods Mol. Biol. Clifton NJ. 704, 187–195 (2011).
  Medline CASGoogle Scholar
• 5. Mordorski B, Costa-Orlandi CB, Baltazar LM et al. Topical nitric oxide releasing nanoparticles are effective in a murine model of dermal Trichophyton rubrum dermatophytosis. Nanomed. Nanotechnol. Biol. Med. 13(7), 2267–2270 (2017).
  CASGoogle Scholar
• 6. Xue B, Yu Y, Peng G, Sun M, Lv P, Li X. Amphotericin B and curcumin co-loaded porous microparticles as a sustained release system against Candida albicans. Mol. Basel Switz. 27(10), 3079 (2022).
  Medline CASGoogle Scholar
• 7. Sanchez DA, Schairer D, Tuckman-Vernon C et al. Amphotericin B releasing nanoparticle topical treatment of Candida spp. in the setting of a burn wound. Nanomed. Nanotechnol. Biol. Med. 10(1), 269–277 (2014).
  CASGoogle Scholar
• 8. Cabrales P, Han G, Roche C, Nacharaju P, Friedman AJ, Friedman JM. Sustained release nitric oxide from long-lived circulating nanoparticles. Free Radic. Biol. Med. 49(4), 530–538 (2010).
  Medline CASGoogle Scholar
• 9. Friedman AJ, Han G, Navati MS et al. Sustained release nitric oxide releasing nanoparticles: characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide Biol. Chem. 19(1), 12–20 (2008).
  Medline CASGoogle Scholar
• 10. Randhawa MA, Gondal MA, Al-Zahrani A-HJ, Rashid SG, Ali A. Synthesis, morphology and antifungal activity of nano-particulated amphotericin-B, ketoconazole and thymoquinone against Candida albicans yeasts and Candida biofilm. J. Environ. Sci. Health Part A Tox. Hazard. Subst. Environ. Eng. 50(2), 119–124 (2015).
  Medline CASGoogle Scholar
• 11. Artunduaga Bonilla JJ, Paredes Guerrero DJ, Sánchez Suárez CI, Ortiz López CC, Torres Sáez RG. In vitro antifungal activity of silver nanoparticles against fluconazole-resistant Candida species. World J. Microbiol. Biotechnol. 31(11), 1801–1809 (2015).
  MedlineGoogle Scholar
• 12. Artunduaga Bonilla JJ, Honorato L, Cordeiro de Oliveira DF et al. Silver chitosan nanocomposites as a potential treatment for superficial candidiasis. Med. Mycol. 59(10), 993–1005 (2021). • Investigated the antifungal activity of silver nanoparticles (AgNPs) and their functionalization in a chitosan matrix. AgNPs were synthesized through an eco-friendly method and their functionalization greatly reduced the cytotoxicity displayed in previous works. They also demonstrated antifungal effect in vivo in a murine model of cutaneous candidiasis and anti-biofilm effect in vitro, suggesting that this particle is a viable candidate for an effective topical treatment of superficial candidiasis.
  MedlineGoogle Scholar
• 13. Ghaffari A, Miller CC, McMullin B, Ghahary A. Potential application of gaseous nitric oxide as a topical antimicrobial agent. Nitric Oxide Biol. Chem. 14(1), 21–29 (2006).
  Medline CASGoogle Scholar
• 14. Mowbray M, Tan X, Wheatley PS, Morris RE, Weller RB. Topically applied nitric oxide induces T-lymphocyte infiltration in human skin, but minimal inflammation. J. Invest. Dermatol. 128(2), 352–360 (2008).
  Medline CASGoogle Scholar
• 15. Macherla C, Sanchez D, Ahmadi M et al. Nitric oxide releasing nanoparticles for treatment of Candida albicans burn infections. Front. Microbiol. 3 (2012). https://www.frontiersin.org/articles/10.3389/fmicb.2012.00193
  MedlineGoogle Scholar
• 16. Ahmadi MS, Lee HH, Sanchez DA et al. Sustained nitric oxide-releasing nanoparticles induce cell death in Candida albicans yeast and hyphal cells, preventing biofilm formation in vitro and in a rodent central venous catheter model. Antimicrob. Agents Chemother. 60(4), 2185–2194 (2016).
  Medline CASGoogle Scholar
• 17. Costa-Orlandi CB, Mordorski B, Baltazar LM et al. Nitric oxide releasing nanoparticles as a strategy to improve current onychomycosis treatments. J. Drugs Dermatol. JDD. 17(7), 717–720 (2018).
  Medline CASGoogle Scholar
• 18. Costa-Orlandi CB, Martinez LR, Bila NM et al. Nitric oxide-releasing nanoparticles are similar to efinaconazole in their capacity to eradicate Trichophyton rubrum biofilms. Front. Cell. Infect. Microbiol. 11, 684150 (2021). •• Investigates the potential of nitric oxide-releasing nanoparticles (NO-NPs) in the context of onychomycosis. Most frequently caused by dermatophytes, onychomycosis usually requires a prolonged treatment that is associated to the biofilm formation phenotype of this fungi. The authors performed an in vitro evaluation of the anti-biofilm activity of NO-NPs against T. rubrum and compared its efficacy with commonly used antifungal drugs such as fluconazole, terbinafine and efinaconazole. Their results proved the potential of NO-NPs against Trichophyton rubrum and that its efficacy was similar to efinaconazole.
  Medline CASGoogle Scholar
• 19. Cleare LG, Li KL, Abuzeid WM, Nacharaju P, Friedman JM, Nosanchuk JD. NO Candida auris: nitric oxide in nanotherapeutics to combat emerging fungal pathogen Candida auris. J. Fungi. 6(2), 85 (2020). •• Investigated the potential of NO-NPs as an antifungal agent against the emerging fungal pathogen Candida auris. This paper is of fundamental importance because it is, to our knowledge, the first and only study so far to evaluate the effect NO-NPs against C. auris, a novel multi-resistant human pathogen. Although further research in the field is needed, this study successful demonstrates the potential of NO-NPs as a therapeutic option against C. auris.
  CASGoogle Scholar
• 20. Liu S, Zamith-Miranda D, Almeida-Paes R, da Silva LBR, Nacharaju P, Nosanchuk JD. Nitric oxide-loaded nano- and microparticle platforms serving as potential new antifungal therapeutics. Fungal Biol. (2023). https://www.sciencedirect.com/science/article/pii/S1878614623000077
  Google Scholar